Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive ratsAn historical account and some follow-up

Cardiovascular Research

Volumn 45, Issue 1, 2000, Pages 79-81

  Pegram, Barbara L ^a   Ishize, Shozo ^a   Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Antihypertensive agents; Heart rate (variability); Hemodynamics; Hypertension; Hypertrophy; Ventricular function

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; HYDRALAZINE; METHYLDOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CORONARY HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTORY; HYPERTENSION; NONHUMAN; NOTE; PRIORITY JOURNAL; RAT; ANIMAL; ARTICLE; BIBLIOMETRICS; DRUG EFFECT; HEART; PATHOPHYSIOLOGY; PHYSIOLOGY; PUBLISHING; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; BIBLIOMETRICS; CLONIDINE; HEART; HISTORY, 20TH CENTURY; HYDRALAZINE; HYPERTENSION; METHYLDOPA; PUBLISHING; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 0033990614     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00290-4     Document Type: Note

References (33)

1. Pegram B.L., Ishise S., Frohlich E.D. Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar-Kyoto and spontaneously hypertensive rats. Cardiovasc Res. 16:1982;40-46.
2. Kannel W.B., Dawber T.R., Kagan A., Revotskie V., Stokes J. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Heart Study. Ann Intern Med. 55:1961;44-50.
3. Kannel W.B., Gordon T., Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham Study. Ann Intern Med. 71:1969;89-105.
4. Frohlich E.D. Hemodynamics and other determinants in development of left ventricular hypertrophy: Conflicting factors in its regression. Fed Proceed. 42:1983;2709-2715.
5. Frohlich E.D. Physiological considerations in left ventricular hypertrophy. Am J Med. 75:(3A):1983;12-18.
6. Sen S., Tarazi R.C., Khairallah P.A., Bumpus F.M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 35:1974;775-781.
7. Sen S., Smeby R.R., Bumpus F.M. Renin in spontaneously hypertensive rats. Circ Res. 31:1972;876-880.
8. Sen S., Bumpus F.M. Collagen synthesis in development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Am J Cardiol. 44:1979;954-958.
9. Sen S., Tarazi R.C., Bumpus F.M. Biochemical changes associated with development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc Res. 10:1976;254-261.
10. Sen S., Tarazi R.C., Bumpus F.M. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res. 11:1977;427-433.
11. Ishise S., Pegram B.L., Frohlich E.D. Disparate affects of methyldopa and clonidine on cardiac mass and haemodynamics in rats. Clin Sci. 59:(VI):1980;449s-452s.
12. Dunn F.G., Frohlich E.D. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Pharmacotherapy. 1:1981;188-197.
13. Kuwajima I., Kardon M.B., Pegram B.L., Sesoko S., Frohlich E.D. Regression of left ventricular hypertrophy in two-kidney, one clip Goldblatt hypertension. Hypertension. 4:1982;113-118.
14. Tarazi R.C., Frohlich E.D. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation. 75:(I):1987;113-117.
15. Frohlich E.D. Potential mechanisms explaining the risk of left ventricular hypertrophy. Am J Cardiol. 59:(A):1987;91-97.
16. Frohlich E.D. (State of the Art): The heart in hypertension: Unresolved conceptual challenges. Hypertension. 11:(I):1988;19-24.
17. Frohlich E.D. (State of the Art): The First Irvine H. Page Lecture: The mosaic of hypertension: Past, present and future. J Hypertens. 6:1988;S2-S11.
18. Frohlich E.D. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardio. 21:1989;3-10.
19. Frohlich E.D. Is reversal of left ventricular hypertrophy in hypertension beneficial? Hypertension. 18:1991;133-138.
20. Frohlich Ed. The heart in hypertension: A Overview. Hypertension. 18:1991;62-68.
21. Frohlich E.D., Arthur C. Corcoran Memorial Lecture: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension. 29:1997;188-193.
22. Sasaki O., Kardon M.B., Pegram B.L., Frohlich E.D. Aortic distensibility and left ventricular pumping ability after methyldopa in Wistar-Kyoto and spontaneously hypertensive rats. J Vascular Med. 1:1989;59-66.
23. Frohlich E.D., Sasaki O. Dissociation of changes in cardiovascular mass and performance with angiotensin converting enzyme inhibitors in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol. 16:1990;1492-1499.
24. Ando K., Frohlich E.D., Chien Y., Pegram B.L. Effects of quinapril on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vascular Med Biol. 3:1991;117-123.
25. Frohlich E.D., Sasaki O., Chien Y., Arita M. Changes in cardiovascular mass, left ventricular pumping ability, and aortic distensibility after calcium antagonist in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens. 10:1992;1369-1378.
26. Natsume T., Kardon M.B., Pegram B.L., Frohlich E.D. Ventricular performance in spontaneously hypertensive rats with reduced cardiac mass. Cardiovasc Drug Ther. 3:1989;433-439.
27. Aristizabal D., Messerli F.H., Frohlich E.D. Disparate structural effects of left and right ventricles by angiotensin converting enzyme inhibitors and calcium antagonists. Am J Cardiol. 73:1994;483-487.
28. Arita M., Horinaka S., Frohlich E.D. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 11:1993;951-959.
29. Arita M., Horinaka S., Komatsu K., Frohlich E.D. Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens. 11:1993;S354-355.
30. Frohlich E.D. Hypertensive cardiovascular disease. A pathophysiological assessment. Hypertension. 6:1984;934-939.
31. Frohlich E.D. Current clinical pathophysiologic considerations in essential hypertension. Med Clin North Am. 81:1997;1113-1129.
32. Francischetti A., Ono H., Frohlich E.D. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension. 31:1998;795-801.
33. Frohlich E.D. Hypertension: evaluation and treatment. 1998;212 Williams & Wilkins Publishers, Baltimore.